Working… Menu

Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03178708
Recruitment Status : Completed
First Posted : June 7, 2017
Last Update Posted : January 12, 2021
Information provided by (Responsible Party):
Ghada Mohammed AboelFadl, Assiut University

Brief Summary:
During the surgical procedure of scoliosis correction, large surgery extent and long-lasting strong nociceptive stimulation lead to postoperative pain formation of greater intensity compared with other orthopedic interventions. In these patients, duration of postoperative symptoms is longer, and may lead to persistent pain formation due to developing neuroplastic changes in the central nervous system.

Condition or disease Intervention/treatment Phase
Spinal Curvatures Drug: Group A amantadine sulfate Other: Group B ringer lactate Phase 2 Phase 3

Detailed Description:

Instrumentation in correction operations for spinal deformities as vertebral fusion, congenital and traumatic scoliosis, carries a 0.5-5% risk of injuring the spinal cord during spinal surgery.

These complications are generally results of complex factors such as direct effects of compression on the spinal cord, distraction, the effects of spinal ischemia or arterial hypotension.

The purpose of the wake-up test is to monitor voluntary motor function of the lower limbs once the vertebrae have been instrumented and distracted. The depth of anesthesia is gradually lightened up to the point where patients are able to respond to verbal commands. As the voluntary movement of lower extremities is demonstrated, the depth of anesthesia is increased to complete the surgery.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: the role of preoperative administration of Amantadine Sulphate on the duration of wake up test and postoperative opiod consumption in patients undergoing major spine deformities corrective surgeries.
Masking: Double (Participant, Care Provider)
Primary Purpose: Treatment
Official Title: The Implications of Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients as Regard Its Effect on the Duration of Wake up Test and Postoperative Opioid Consumption
Actual Study Start Date : August 1, 2017
Actual Primary Completion Date : December 30, 2019
Actual Study Completion Date : December 30, 2019

Arm Intervention/treatment
Active Comparator: Group A amantadine sulfate
the patients will receive amantadine sulfate infusion using the dose 200 mg slowly I.V 3 hours prior to the surgery
Drug: Group A amantadine sulfate
infusion solution for slowly intravenous application 3 hours preoperative
Other Name: PK-Merz Infusion amantadine sulfate

Placebo Comparator: Group B ringer lactate
the patients will receive 500 ml ringer lactate infusion slowly i.v 3 hours prior to surgery.
Other: Group B ringer lactate
infusion solution for intravenous application 3 hours preoperative
Other Names:
  • ringer lactate
  • Lactated ringer

Primary Outcome Measures :
  1. postoperative opioid consumption [ Time Frame: 24 hours postoperative ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Being candidate for spine deformity correction surgery(scoliosis and kyphosis )
  2. Willing to participate in the study

Exclusion Criteria:

  1. Patient refusal
  2. Patients with chronic kidney, lungs,Gastrointestinal tract, liver, or cardiovascular diseases.
  3. Pregnant or breastfeeding women.
  4. Allergy to any of the study medications and taking medications that could significantly interact with amantadine (tramadol, atropine,antipsychotic medications)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03178708

Layout table for location information
Assiut governorate
Assiut, Egypt
Sponsors and Collaborators
Assiut University
Publications of Results:
Layout table for additonal information
Responsible Party: Ghada Mohammed AboelFadl, Principal Investigator, Assiut University Identifier: NCT03178708    
Other Study ID Numbers: IV amantadine
First Posted: June 7, 2017    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Curvatures
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Antiparkinson Agents
Anti-Dyskinesia Agents
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents